Provided by Tiger Trade Technology Pte. Ltd.

ASCENTAGE-B

42.080
-0.600-1.41%
Volume:2.82M
Turnover:116.05M
Market Cap:15.70B
PE:-31.35
High:42.300
Open:41.400
Low:40.540
Close:42.680
52wk High:95.350
52wk Low:31.350
Shares:373.00M
HK Float Shares:373.00M
Volume Ratio:1.48
T/O Rate:0.75%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-1.342
ROE:-159.65%
ROA:-22.77%
PB:20.71
PE(LYR):-31.35
PS:35.32

Loading ...

Ascentage Pharma Group International Director Ye Changqing Files Initial Beneficial Ownership Statement

Reuters
·
Mar 19

Ascentage Pharma Group International director Marc E. Lippman files initial beneficial ownership statement

Reuters
·
Mar 19

Ascentage Pharma Group International files Form 3 initial beneficial ownership statement for director Debra Yu

Reuters
·
Mar 19

Assessing Ascentage Pharma Group International’s Valuation After AACR 2026 Preclinical Oncology Selections

Simply Wall St.
·
Mar 19

ASCENTAGE-B to Present Four Preclinical Studies at 2026 AACR Annual Meeting

Stock News
·
Mar 18

Ascentage Pharma to present four preclinical study posters at AACR Annual Meeting 2026

Reuters
·
Mar 18

Ascentage Pharma-B (06855.HK) Sets 25 Mar 2026 Board Meeting to Approve FY2025 Results and Consider Final Dividend

Bulletin Express
·
Mar 13

Ascentage Pharma Group International Schedules Full-Year 2025 Unaudited Financial Results Release

Reuters
·
Mar 11

Ascentage Pharma to Report Full Year 2025 Unaudited Financial Results and Provide Business Updates on March 25, 2026

THOMSON REUTERS
·
Mar 11

ASCENTAGE-B (06855) Announces February 2026 Monthly Return

Bulletin Express
·
Mar 06

Assessing Ascentage Pharma Group International (SEHK:6855) Valuation After Recent Share Price Volatility

Simply Wall St.
·
Feb 28

Ascentage Pharma to Participate in Three Upcoming Investor Conferences

Reuters
·
Feb 23

Is Ascentage Pharma Group International (SEHK:6855) Pricing Reflect A 23.3% One‑Year Gain?

Simply Wall St.
·
Feb 19

Assessing Ascentage Pharma Group International (SEHK:6855) Valuation After Recent Share Price Volatility

Simply Wall St.
·
Feb 14

Ascentage Pharma to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026

Reuters
·
Feb 09

Ascentage Pharma Announces Ind Clearance by the China Cde for Btk Degrader Apg-3288

THOMSON REUTERS
·
Feb 06

China erteilt Ascentage Pharma IND-Genehmigung für BTK-Degrader APG-3288

Reuters
·
Feb 06

Ascentage Pharma (06855) Announces January 2026 Monthly Return

Bulletin Express
·
Feb 05

ASCENTAGE-B Stock Surges Over 3% in Intraday Trading as BTK Degrader Class 1 New Drug APG-3288 Tablets Gain Clinical Approval

Deep News
·
Feb 04

Ascentage Pharma Outlines 2026 Global Innovation Strategy with Focus on Expanding Clinical Development, Advancing Product Commercialization, and Accelerating Pipeline Innovation in Hematologic Malignancies and Solid Tumors

Reuters
·
Jan 15